Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Clobetasol Propionate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 6/20 | 1.00 |
| ▸ | PGR | P06401 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | USP2 | O75604 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | CYP3A5 | P20815 | 1/20 | 1.00 |
| ▸ | PPARG | P37231 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.84 |
| ▸ | DRD2 | P14416 | 1/20 | 0.84 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.84 |
| ▸ | MEN1 | O00255 | 1/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clobetasol Propionate SCHEMBL5577907 | 1.00 | PGR (1.00) | PGRNR3C1CYP3A4USP2LMNA | |
| Clobetasol Propionate SCHEMBL17131797 | 1.00 | PGR (1.00) | PGRNR3C1CYP3A4USP2LMNA | |
| Clobetasol Propionate SCHEMBL11052078 | 1.00 | PGR (1.00) | PGRNR3C1CYP3A4USP2LMNA | |
| Clobetasol Propionate SCHEMBL11052079 | 1.00 | PGR (1.00) | PGRNR3C1CYP3A4USP2LMNA | |
| Clobetasol Propionate SCHEMBL445257 | 1.00 | PGR (1.00) | PGRNR3C1CYP3A4USP2LMNA | |
| Clobetasol Propionate SCHEMBL5577908 | 1.00 | PGR (1.00) | PGRNR3C1CYP3A4USP2LMNA | |
| Clobetasol Propionate SCHEMBL10865006 | 1.00 | PGR (1.00) | PGRNR3C1CYP3A4USP2LMNA | |
| Clobetasol Propionate SCHEMBL28118983 | 0.98 | NR3C1 (0.95) | PGRNR3C1CYP3A4USP2LMNA | |
| Betamethasone Dipropionate SCHEMBL18301225 | 0.95 | NR3C1 (0.93) | PGRNR3C1CYP3A4USP2LMNA | |
| SCHEMBL596943 | 0.94 | NR3C1 (0.88) | PGRNR3C1CYP3A4USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 34992 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137656-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | SPARROW PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260137657-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | SPARROW PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260139030-A1 | CHIMERIC PROTEINS FOR TREATING CUTANEOUS INFLAMMATION | SHATTUCK LABS INC (US) | 2026-05-21 | — | — | US | claimed |
| EP-4744657-A1 | THERAPEUTIC AGENT FOR HUMAN GRAFT VERSUS HOST DISEASE AND COMBINATION THEREOF | National University Corporation Okayama University (JP) | 2026-05-20 | — | — | EP | claimed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| US-20260130899-A1 | METHOD OF TREATMENT FOR PREVENTION OF GLUCOCORTICOID TOXICITY AND/OR ENHANCEMENT OF MUSCLE REGENERATION VIA NEUTROPHIL ELASTASE INHIBITION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2026-05-14 | — | — | US | claimed |
| EP-4741421-A1 | FAB-ARM EXCHANGE-PREVENTING FC VARIANTS FROM WHICH EFFECTOR FUNCTIONS ARE REMOVED | Korea University Research and Business Foundation (KR) | 2026-05-13 | — | — | EP | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-3222270-B1 | COMPOSITIONS FOR MUCOSAL ADHESION AND USES THEREOF | BIONANOPLUS S L (ES) | 2026-04-29 | — | — | EP | claimed |
| US-20260103492-A1 | CYCLOSPORINE COMPOSITIONS AND METHODS OF USE | BACAINN BIOTHERAPEUTICS, LTD. (KY) | 2026-04-16 | — | — | US | claimed |
| EP-0216453-A2 | Esters of hyaluronic acid and their salts. | FIDIA S.p.A. (IT) | 1987-04-01 | — | — | EP | claimed |
| EP-0197718-A2 | New medicaments for topical use | FIDIA S.p.A. (IT) | 1986-10-15 | — | — | EP | claimed |
| EP-0173478-A1 | Treatment of skin disorders | SCOTIA HOLDINGS PLC (GB) | 1986-03-05 | — | — | EP | claimed |
| EP-0068553-B1 | TOPICAL ANTIMICROBIAL ANTI-INFLAMMATORY COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 1985-11-21 | — | — | EP | claimed |
| US-4370322-A | BETAMETHASONE, BECLOMETHASONE AND CLOBETASOL DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1983-01-25 | — | — | US | claimed |
| EP-0068553-A1 | Topical antimicrobial anti-inflammatory compositions | THE PROCTER & GAMBLE COMPANY (US) | 1983-01-05 | — | — | EP | claimed |
| US-4343798-A | Topical antimicrobial anti-inflammatory compositions | THE PROCTER & GAMBLE COMPANY (US) | 1982-08-10 | — | — | US | claimed |
| US-4333927-A | CORTICOSTEROID, PHOSPHATIDE, BUTYLHYDROXYANISOLE AND/OR BUTYLHYDROXYTOLUENE | MITSUBISHI CHEMICAL INDUSTRIES, LTD. (JP) | 1982-06-08 | — | — | US | claimed |
| US-4244942-A | Creamy preparation containing steroid and process for the preparation thereof | TOKO YAKUHIN KOGYO KABUSHIKI KAISHA (JP) | 1981-01-13 | — | — | US | claimed |
| US-4083974-A | Topical steroidal anti-inflammatory preparations containing polyoxypropylene 15 stearyl ether | THE UPJOHN COMPANY (US) | 1978-04-11 | — | — | US | claimed |